A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Recent college reforms envisage offering more flexible degrees, creating online learning tools, and inviting foreign universities to set up campuses in India. However, large gaps remain between rural and urban areas. School quality, campus building conditions, and computer access vary substantially based on a student's gender and family's wealth. Poor job prospects for graduates and uneven rule enforcement across different states have faced criticism from researchers and the public alike.
== Academic fields == Critical legal studies, school of legal philosophy Constrained least square statistical estimator CLs method to set bounds on particle physics model parameters The .cls file extension, used to hold LaTeX manuscripts - see LaTeX § Compatibility and converters
=== ANDI-MS or netCDF === The Analytical Data Interchange Format for Mass Spectrometry is a format for exchanging data. Many mass spectrometry software packages can read or write ANDI files. ANDI is specified in the ASTM E1947 Standard. ANDI is based on netCDF which is a software tool library for writing and reading data files. ANDI was initially developed for chromatography-MS data and therefore was not used in the proteomics gold rush where new formats based on XML were developed.
A multiple fruit such as a fig or mulberry is formed from a cluster of flowers, an inflorescence. Each ('smallish') flower produces a single fruitlet, which, as all develop, all merge into one mass of fruit.
=== Boiling or steam seasoning === Submersion in boiling water or the application of steam speeds the drying of wood. This method is said to cause less shrinkage, "… but it is expensive to use, and reduces the strength and elasticity of the timber."
Sources: en.wikipedia.org
The class of nitazene opioids is defined chemically by the presence of the benzimidazole core structure and pharmacologically by μ opioid agonism. Nitazenes are benzimidazoles that are substituted with a dialkylaminoethyl group at the 1-position, in the 2-position with a substituted benzyl group and often in the 5-position, usually with a nitro group but sometimes with other substitutions. Compounds substituted in the 6-position are less effective, while the 4- or 7-substituted compounds are not analgesically active. Analgesically active nitazenes are also usually substituted in the para-position of the benzyl group, and only rarely in the ortho or meta positions. At the methylene linker, a methyl or an amide group is tolerated stereospecifically by the target receptor, and this carbon can also be replaced by CH2CH2, S, or NCH3 with reduced but in some cases still significant activity. Nitazenes are structurally unrelated to most other opioids, but have structural similarity to benzimidazole derivatives from the orphine group, as well as to viminol and its analogues. The compounds are derived from the historical prototype 1-(β-diethylaminoethyl)-2-benzylbenzimidazole (desnitazene). The replacement of the N,N-dialkylamino unit by pyrrolidinyl or piperidinyl, which is found in nitazepyne and nitazepipne compounds, falls into the spectrum of designer drugs. Substitution of the benzyl for thienylmethyl, pyridylmethyl, α-napthylmethyl or styryl has a potency-reducing effect.
An embalmer is someone who has been trained and qualified in the art and science of sanitization, presentation, and preservation of the human deceased. The term mortician is far more generic; it may refer to someone who is a funeral director, an embalmer, or just a person who prepares the deceased, with or without the formal qualification of an embalmer. Thus while all embalmers are morticians, many morticians are not embalmers and the terms are not intrinsically synonymous. Embalming training commonly involves formal study in anatomy, thanatology, chemistry, and specific embalming theory (to widely varied levels depending on the region of the world one lives in) combined with practical instruction in a mortuary with a resultant formal qualification granted after the passing of a final practical examination and acceptance into a recognized society of professional embalmers. The roles of a funeral director and embalmer are different, depending on local customs and the licensing body of the region in which they both operate. A funeral director arranges for the final disposition of the deceased, and may or may not prepare the deceased (by embalming, preparing for viewing or other legal requirements). Legal requirements over who can practice vary geographically. Some regions or countries do not have specific requirements, while others have clear prohibitions. In the United States, the title of an embalmer is largely based on the state in which they are licensed.
Shānghán Zábìng Lùn (傷寒雜病論), or The Treatise on Cold Damage and Miscellaneous Diseases, is the first Chinese monograph on diseases by Zhang Zhongjing. The original work is lost, but most of its contents are preserved in two extant works called Shānghán Lùn (傷寒論; "The Treatise on Cold Damage") and Jīnguì Yàolüè (金匱要略; "Essential Prescriptions from the Golden Chamber"). The first work primarily addresses externally triggered conditions while the latter work describes internally generated conditions. Zhang's specialized chapter on xiāo kě is found in Shānghán Lùn and Jīnguì Yàolüè. Nine subsections and nine formulae (herbal remedies) on wasting-thirst were recorded. The text proposed a theory of "three wasting-thirsts": upper- (associated with the lungs), middle- (associated with the stomach), and lower- (associated with the kidneys), all three of which shared excessive urine and thirst as symptoms. This theory was later expanded through the works of Liu Wansu (1120–1200 AD) and Wang Kentang (1549–1613 AD). According to Liu, "lower wasting-thirst" attributed to "kidney-yin deficiency" was associated with sweet urine (glycosuria). This may indicate differentiation akin to modern-day differentiation of diabetes mellitus and diabetes insipidus.
=== Intracellular transport === Little is known about intracellular kinetics of thyroid hormones. However, recently it could be demonstrated that the crystallin CRYM binds 3,5,3′-triiodothyronine in vivo.
The DSQ is a questionnaire designed to measure difficulty swallowing associated with eosinophilic esophagitis, with total scores ranging from 0 to 84; higher DSQ scores indicate worse symptoms. The efficacy and safety of dupilumab to treat prurigo nodularis among adults were evaluated in two clinical trials, EFC16459 (PRIME) and EFC16460 (PRIME2). Each trial evaluated 300 mg of dupilumab administered every 2 weeks following an initial dose of 600 mg. The treatment lasted for 24 weeks. Effectiveness was mainly assessed by the proportion of subjects whose itchy skin (pruritus) improved by more than four points on the Worst Itch Numeric Rating Scale, the proportion of subjects who achieved score of 0 or 1 on Investigator's Global Assessment PN-stage scale (the equivalent of 0-5 nodules), and the proportion of subjects who achieved a response on both scales at week 24. In June 2026, Alteogen disclosed that Sanofi had been utilizing its ALT-B4 recombinant human hyaluronidase platform since 2019 to develop a high-dose subcutaneous formulation of dupilumab.
Sources: en.wikipedia.org
sovramagnificentissimamente (cited by Dante Alighieri in De vulgari eloquentia), 27 letters, "in a way that is more than magnificent by far" (archaic); incontrovertibilissimamente, 27 letters, "in a way that is very difficult to falsify"; particolareggiatissimamente, 27 letters, "in an extremely detailed way"; anticostituzionalissimamente, 28 letters, "in a way that strongly violates the constitution". The longest accepted neologism is psiconeuroendocrinoimmunologia (30 letters).. Other long words are:
The insulin produced by bacteria, branded Humulin, was approved for release by the Food and Drug Administration in 1982. In 1988, the first human antibodies were produced in plants. In 1987, a strain of Pseudomonas syringae became the first genetically modified organism to be released into the environment when a strawberry and potato field in California were sprayed with it. The first genetically modified crop, an antibiotic-resistant tobacco plant, was produced in 1982. China was the first country to commercialize transgenic plants, introducing a virus-resistant tobacco in 1992. In 1994, Calgene attained approval to commercially release the Flavr Savr tomato, the first genetically modified food. Also in 1994, the European Union approved tobacco engineered to be resistant to the herbicide bromoxynil, making it the first genetically engineered crop commercialized in Europe. An insect resistant Potato was approved for release in the US in 1995, and by 1996 approval had been granted to commercially grow 8 transgenic crops and one flower crop (carnation) in 6 countries plus the EU. In 2010, scientists at the J. Craig Venter Institute announced that they had created the first synthetic bacterial genome. They named it Synthia and it was the world's first synthetic life form. The first genetically modified animal to be commercialized was the GloFish, a Zebra fish with a fluorescent gene added that allows it to glow in the dark under ultraviolet light. It was released to the US market in 2003.
== Gene == Alternative splicing results in two transcript variants encoding the same protein. This gene and the gene that encodes ribonuclease, RNase A family, 4 share promoters and 5' exons. Each gene splices to a unique downstream exon that contains its complete coding region.
Chicken McNuggets are sold in various portion sizes depending on the country of purchase. In the United States, they come in packs of 4, 6, 10, 20 and 50 (in selected stores). In some markets, including the United Kingdom, they are sold in packs of 4 (as part of a Happy Meal), 6, 9 or 20 (as a "ShareBox"). In New Zealand and Australia, they were also available in 3-packs in Happy Meals and Heart Foundation-approved "Tick healthy" meals. In Canada, Chicken McNuggets are sold in packs of 4 (as part of a Happy Meal), 6, 10, and 20. A 50-piece McNuggets meal deal has been promoted at times for special events such as the NFL's Super Bowl. They have recently been introduced by McDonald's in India, first as a part of its "Breakfast Meal" and later in the regular menu in May 2009. A halal version of the McNuggets has been sold at two franchises in Dearborn, Michigan, beginning in the early 2000s, bringing in double the average sales of regular McNuggets.
The first human to human heart transplantation was performed in 1967 by the South African surgeon Christiaan Barnard at Groote Schuur Hospital in Cape Town. This marked an important milestone in cardiac surgery, capturing the attention of both the medical profession and the world at large. However, long-term survival rates of patients were initially very low. Louis Washkansky, the first recipient of a donated heart, died 18 days after the operation while other patients did not survive for more than a few weeks. The American surgeon Norman Shumway has been credited for his efforts to improve transplantation techniques, along with pioneers Richard Lower, Vladimir Demikhov and Adrian Kantrowitz. By mid-2018, the International Society for Heart and Lung Transplantation registry had recorded more than 146,000 heart transplantations worldwide. The first successful transplant of a heart from a genetically modified pig to a human was performed on 7 January 2022 in Baltimore by heart surgeon Bartley P. Griffith. The recipient, 57-year-old David Bennett, survived for 60 days before dying on 8 March 2022. By the middle of the 20th century, heart disease had surpassed infectious disease as the leading cause of death in the United States, and it is currently the leading cause of deaths worldwide. Since 1948, the ongoing Framingham Heart Study has shed light on the effects of various influences on the heart, including diet, exercise, and common medications such as aspirin.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.